We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A BALANCING VIEW: Lifetime Channeling of Infliximab for Crohn's Disease.
- Authors
Hanauer, Stephen B.
- Abstract
The article discusses the channeling of infliximab for Crohn's disease. Infliximab is currently indicated for reducing signs and symptoms and inducing and maintaining clinical remission in patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy and for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in patients with fistulizing Crohn's disease. The expectations and requisites for long-term therapy after induction of remission with infliximab are no different than they are for corticosteroids or cyclosporine or for maintenance therapy with azathioprine or methotrexate.
- Subjects
CROHN'S disease; INFLIXIMAB; ADRENOCORTICAL hormones; FISTULA; PATIENTS; THERAPEUTICS
- Publication
American Journal of Gastroenterology (Springer Nature), 2005, Vol 100, Issue 7, p1438
- ISSN
0002-9270
- Publication type
Article
- DOI
10.1111/j.1572-0241.2005.50622_3.x